Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer
Sign Up to like & getrecommendations! Published in 2021 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2021.1982698
Abstract: ABSTRACT Introduction Although various new drugs have been developed, the prognosis of therapeutic advances for metastatic gastric cancer is insufficient. Trastuzumab deruxtecan (T-DXd), a new human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate (ADC),… read more here.
Keywords: gastric cancer; her2 targeting; trastuzumab deruxtecan; cancer ... See more keywords
Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac144
Abstract: Abstract Background Trastuzumab deruxtecan (T-DXd) has shown durable antitumor activity in pretreated patients with HER2-positive advanced breast cancer (ABC), but its efficacy has not yet been evaluated in patients with active brain metastases (BMs). DEBBRAH… read more here.
Keywords: central nervous; nervous system; breast cancer; cohort ... See more keywords
Pneumocystis jirovecii pneumonia in a patient treated with trastuzumab-deruxtecan
Sign Up to like & getrecommendations! Published in 2023 at "BMJ Case Reports"
DOI: 10.1136/bcr-2022-253647
Abstract: Trastuzumab-deruxtecan (T-DXd) is a novel antibody drug conjugate that has improved treatment outcomes in patients with ERBB2-positive cancer, including locally advanced or metastatic gastric and gastro-oesophageal junction adenocarcinoma. One of the reported side effects of… read more here.
Keywords: patient treated; pneumocystis jirovecii; patient; drug ... See more keywords
Abstract 2273: Soluble TNFα blockade improves effectiveness of trastuzumab deruxtecan and boosts antitumor potential of macrophages in a HER2+ tumor model
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2273
Abstract: Clinical trials showed that trastuzumab deruxtecan (T-DXd) provides durable responses for patients with HER2+ and HER2 low metastatic breast cancer (BC), determined by immunohistochemistry. Approximately 50% of patients with HER2+ metastatic BC were still alive… read more here.
Keywords: trastuzumab deruxtecan; dxd dxd; dxd; blockade ... See more keywords
Abstract 3995: Trastuzumab deruxtecan, antibody-drug conjugate targeting HER2, effectively inhibits growth of patient-derived xenograft model with CIC-rearranged sarcoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3995
Abstract: Background: Capicua-double homeobox 4 (CIC-DUX4)-rearranged sarcomas (CDS) are extremely rare and highly aggressive sarcomas. There is no standard therapy for the patients with advanced CDS, and therapeutic development is needed. We evaluated preclinical efficacy of… read more here.
Keywords: cic; pdx; dxd; patient derived ... See more keywords
Abstract LB219: Inducing significant and efficient tumor growth inhibition vs trastuzumab deruxtecan with low drug-load topoisomerase 1 inhibitor ADC using novel peptide linkers for payload conjugation
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb219
Abstract: The Araris’ site-specific and one-step linker conjugation technology aims at generating stable, safe and highly potent ADCs without the need for antibody engineering prior to payload conjugation. Here, we generated an anti-HER2 ADC using a… read more here.
Keywords: payload; trastuzumab deruxtecan; tumor; inhibitor ... See more keywords
A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.4000
Abstract: 4000Background: T-DXd is an antibody-drug conjugate composed of an anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. Early studies have shown promising... read more here.
Keywords: trastuzumab deruxtecan; study trastuzumab; phase multicenter; open label ... See more keywords
Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan
Sign Up to like & getrecommendations! Published in 2022 at "CNS Oncology"
DOI: 10.2217/cns-2022-0010
Abstract: Antibody–drug conjugates have transformed the treatment of HER2+ breast and other cancers. Unfortunately, the CNS remains a sanctuary site for many such patients in part due to poor macromolecule penetration across the blood–brain tumor barrier.… read more here.
Keywords: trastuzumab deruxtecan; complete response; brain; her2 breast ... See more keywords
Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0214
Abstract: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of a humanized monoclonal anti-HER2 antibody, a cleavable tetrapeptide-based linker and a potent topoisomerase I inhibitor. The drug's efficacy has been proven in HER2-positive breast and gastric… read more here.
Keywords: tract cancer; trial; her2 positive; trastuzumab deruxtecan ... See more keywords
Evolving Treatment Landscape of HER2-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15041286
Abstract: Simple Summary By coupling the potency of cytotoxic chemotherapy with the selectivity of targeted therapy, antibody–drug conjugates represent a unique and rapidly growing class of antitumor agents. In this review, we aim to outline the… read more here.
Keywords: her2 mutant; non small; her2; small cell ... See more keywords
Metastatic Parotid Gland Carcinoma With ERBB2 Amplification With Complete Response to Fam-Trastuzumab Deruxtecan.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2021.7089
Abstract: HER2 mutations have been shown to be targetable in select cases of salivary gland cancers with overexpression or amplification of the HER2 oncogene. Fam-trastuzumab deruxtecan, a novel antibody-drug conjugate that combines trastuzumab with a topoisomerase… read more here.
Keywords: fam trastuzumab; her2; gland; gland carcinoma ... See more keywords